翻译尚未完成，当前显示原文。
Novo NVO reported adjusted third-quarter 2026 earnings of 89 cents per American Depositary Receipt (ADR), beating the Zacks Consensus Estimate of 81 cents. Adjusted earnings declined 12% year over year in Danish kroner from $1.03 per ADR in the prior-year quarter. Revenues of $12.19 billion increased 4% year over year at constant exchange rates (CER) and surpassed the consensus estimate of $11.39 billion. Obesity medicines drove growth, with the Wegovy pill generating DKK 5.39 billion. All reported sales growth rates below are year-over-year at CER. NVO's Q3 Results in Detail Obesity and Diabetes sales rose 3% to DKK 73.69 billion. Obesity Care jumped 22% to DKK 26.15 billion on higher GLP-1 volumes, while Diabetes Care declined 5% to DKK 47.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。